Pleomorphic carcinoma is a rare type of cancer that most often starts in the lung. The word “pleomorphic” means the cancer cells come in many different shapes and sizes when viewed under a microscope. This mixed, messy appearance is what sets it apart from more common lung cancers, and it affects how the disease behaves and how doctors approach treatment.
What Is Pleomorphic Carcinoma?
Pleomorphic carcinoma is a subtype of non-small cell lung cancer (NSCLC). It is classified as a sarcomatoid carcinoma — a group of lung cancers that contain both ordinary carcinoma cells and cells that look like sarcoma (a cancer of bone, muscle, or connective tissue).
Under the microscope, at least 10 percent of the tumor must show these spindle-shaped or giant cells for it to qualify as pleomorphic carcinoma. That threshold comes from the World Health Organization’s classification of lung tumors, which is the standard pathologists use worldwide.
It is uncommon. Pleomorphic carcinoma makes up a small fraction of all lung cancers — often cited as roughly 0.1 to 0.4 percent in surgical series, though estimates vary because these tumors are frequently grouped with other sarcomatoid cancers. Because it is rare, most of what is known comes from case reports and small retrospective studies rather than large clinical trials.
One thing worth clarifying: pleomorphic carcinoma is not the same as a pleomorphic adenoma, which is a common benign salivary gland tumor. The names sound alike, but they are completely different conditions. If you have read about “pleomorphic” tumors and felt confused, that distinction is usually the reason.
What Are the Symptoms of Pleomorphic Carcinoma?
The symptoms are largely the same as those of other lung cancers, because the tumor grows in the same organs. Early on, there may be no symptoms at all.
When symptoms do appear, they commonly include:
- A cough that does not go away or gets worse
- Coughing up blood or rust-colored sputum
- Shortness of breath
- Chest pain, especially when breathing deeply, coughing, or laughing
- Hoarseness
- Unexplained weight loss and loss of appetite
- Fatigue
- Recurring respiratory infections such as bronchitis or pneumonia
These symptoms are not specific to pleomorphic carcinoma. Many of them overlap with far more common conditions like chronic bronchitis, asthma, or a lingering infection. That overlap is why lung cancer is sometimes found late — the early signs are easy to attribute to something else.
Because pleomorphic carcinoma tends to grow in the outer parts of the lung (the periphery) and can spread along surfaces, some people first notice chest wall pain or fluid around the lung. These presentations are described in case reports, but they are not unique to this subtype.
If you have persistent respiratory symptoms lasting more than a few weeks, or any coughing up of blood, that warrants medical evaluation regardless of the cause.
How Is It Diagnosed?
Diagnosis requires a tissue sample. Imaging alone cannot confirm pleomorphic carcinoma.
The process usually starts with imaging — a chest X-ray or, more often, a CT scan. If something suspicious appears, the next step is a biopsy. This may be done with a needle through the chest wall, during a bronchoscopy (a tube passed through the airway), or through surgery to remove part of the tumor.
The biopsy sample goes to a pathologist, who examines it under a microscope and often runs additional tests. The diagnosis depends on finding that mix of carcinoma cells and sarcoma-like cells, with at least 10 percent of the tumor showing the spindle or giant cell pattern.
Doctors also test the tumor for specific molecular markers. These can include EGFR, ALK, ROS1, and PD-L1. The results matter because they can open the door to targeted therapies or immunotherapy. Testing is now standard practice for non-small cell lung cancers generally, and pleomorphic carcinoma is included in that guidance even though the evidence specific to this subtype is thinner.
How Is Pleomorphic Carcinoma Treated?
There is no treatment designed specifically for pleomorphic carcinoma. Because it is rare, it is generally treated like other non-small cell lung cancers, guided by the stage of the disease and the tumor’s molecular profile.
Surgery is often the first option when the cancer is caught early and has not spread. Removing the tumor — along with nearby lymph nodes — offers the best chance of long-term control in these cases. This is consistent with how early-stage NSCLC is managed.
For cancers that have spread or cannot be removed surgically, treatment may include:
- Chemotherapy, often platinum-based regimens used for NSCLC
- Radiation therapy, sometimes combined with chemotherapy
- Targeted therapy, if the tumor has a matching mutation such as EGFR or ALK
- Immunotherapy, particularly if PD-L1 is expressed
Some research suggests that pleomorphic carcinoma may respond less well to certain treatments than typical lung adenocarcinomas, and that outcomes tend to be worse. But this finding comes from small, retrospective studies — not large randomized trials. It should be read as a general trend, not a certainty for any individual.
Because the evidence is limited, some clinicians treat these tumors more aggressively or enroll patients in clinical trials when possible. That is a reasonable approach given how little is known, but it is not a standardized protocol.
What Is the Outlook?
Pleomorphic carcinoma is generally considered more aggressive than common forms of lung cancer. Studies suggest it may grow faster and spread earlier, and survival statistics tend to be lower than for typical adenocarcinoma of the lung.
That said, the numbers are hard to interpret. Most studies are small, single-center, and retrospective — meaning they look backward at records rather than following patients forward. They also mix together people at very different stages of disease. A person diagnosed at an early stage who has surgery may do well for years, while someone diagnosed after spread faces a much harder course.
The stage at diagnosis remains the single strongest factor in outlook. Molecular features also matter — a tumor with a treatable mutation may respond to targeted therapy in ways that older statistics do not capture.
No specific survival percentage can be quoted reliably for this subtype. Anyone who gives you a precise number is likely working from a small dataset that may not apply to your situation.
What Should You Ask Your Doctor?
If you or someone you care about has been diagnosed with pleomorphic carcinoma, a few questions can help clarify the path forward:
- What stage is the cancer, and has it spread beyond the lung?
- Has the tumor been tested for EGFR, ALK, ROS1, and PD-L1?
- Is surgery an option?
- Would a clinical trial be appropriate?
- What is the goal of treatment — cure, control, or symptom relief?
Because this cancer is uncommon, seeking care at a center that sees a high volume of lung cancer cases may be worth considering. Specialized teams are more likely to have experience with rare subtypes and access to trials.
Frequently Asked Questions
Is pleomorphic carcinoma the same as pleomorphic adenoma?
No. Pleomorphic carcinoma is a rare, aggressive lung cancer, while pleomorphic adenoma is a common benign tumor of the salivary glands. They share a word but are entirely different conditions.
What is the survival rate for pleomorphic carcinoma?
No reliable survival rate can be quoted, because the available studies are small and retrospective. Stage at diagnosis remains the strongest factor, and outcomes vary widely between individuals.
Can pleomorphic carcinoma be cured?
It can be cured in some cases when found early and removed completely with surgery. Once the cancer has spread, cure is generally not possible, and treatment focuses on controlling the disease and managing symptoms.
Does pleomorphic carcinoma respond to immunotherapy?
Some cases do respond, particularly when the tumor expresses PD-L1, and immunotherapy is often considered. The evidence specific to this subtype is limited, so response is not guaranteed.
